Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Nov 05, 2021 1:44pm
114 Views
Post# 34093128

RE:RE:S&P Biotech Index Up 6.2% This Week

RE:RE:S&P Biotech Index Up 6.2% This Week

It's just the worst comparable. What they report makes no sense, it deserves to be ignored.

Their NASH "data" is meaningless, 5 open label patients???. Their cancer data is a dog's dinner. It's clearly cherry-picked, the number of patients reported is going down rather than up even as the number of trials they are picking those patients from is going up. They are reporting astronomical numbers that mean absolutely nothing to me, I believe they are there just to make the naive go "wow".

If at any point you see comparables in any metric with thtx I'd say it's just co-incidental.


longterm56 wrote: The sad truth is that the market is treating us like CYDY ... they also post news with no reaction. I'm not saying we are anything like them, just that the market is treating us similarly. Very sad -LT

SPCEO1 wrote: THTX up 0.3%. That is obviously not good. Hopefully, a new communications effort by new staff will sort out how to get THTX on the biotech radar so that it participates in moves like this in the future. Right now, however, it is a backwater biotech stock that gets no respect.




<< Previous
Bullboard Posts
Next >>